Most so-called gold analysts don’t understand the most fundamental fact about gold: It’s not like other investments. 

Every few generations…

Gold becomes the only asset investors cannot be without. 

That moment is now. I lay it all out for you here – including the four best ways to play the coming gold mania.

Debt is going parabolic as the US added another $1 trillion in debt… in just 71 days. 

Confidence in the US dollar is cracking – as other nations dump US Treasuries and buy gold…

And the world is quietly preparing for a monetary reset that will restore gold’s crown as the king of monetary assets – this time, permanently.

The current bull market in gold will be the last one of our lifetime – and the last one you’ll need if you play your cards right. 

For those who act before “gold fever” hits, this cycle could lead to complete financial transformation for you and your family. It’s coming.

How do I know?

Because one cutting-edge private company is about to roll out a revolutionary gold investment 5,000 years in the making.

Go here for details before this final gold bull market sees its next leg higher.

Best,

Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio

---

Today’s Featured Content

Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum

Written by Thomas Hughes. Published 11/19/2025. 

Key Points

• Medtronic’s turnaround has taken time, but it is here and gaining momentum.
• Analysts and institutional trends indicate accumulation underway.
• Q2 results and the guidance update affirm strength and capital returns in F2026 and beyond.

It has taken Medtronic (NYSE: MDT) considerable time to regain momentum, but it has — and its stock price is on track to move higher.

The chart reflects this shift, showing a bottoming process unfolding over several years.

Tilson: “I’m watching HOOD” (Ad)

A strange chasm is coming to Wall Street…

It’s already creating millionaires and billionaires at the fastest pace in history. CNBC calls it “the largest wealth creation spree in history.” Yet 1 in 3 Americans now fear their financial situation is deteriorating. There’s only one way to survive, says the man who predicted 2008 and 2020, but sadly it’s already too late for many.Everything you need to know is here.

Price action cleared a crucial hurdle in early 2025, formed a Golden Crossover, and confirmed a market reversal after the fiscal year 2026 (F2026) Q2 earnings release.

In this scenario, MDT stock is positioned to rally over the coming quarters — potentially years — as the company sustains modest growth, healthy margins, strong cash flow, and consistent capital returns. 

Medtronic’s stock could advance 20%–30%, potentially more, given the favorable growth outlook. The company is sustaining mid-single-digit growth in F2026, and results are accelerating, prompting guidance upgrades and suggesting consensus forecasts may be conservative.

As of mid-November, the consensus forecasts reported by MarketBeat expect the healthcare company to grow at a mid-single-digit pace over the next five to six years, with incremental margin improvements along the way.

Capital returns are a significant factor — dividends, dividend growth, and share buybacks. The dividend yield of 2.95% is attractive and reliable, and the payout ratio is around 50%, making the current payment easily sustainable.

Dividend increases are likely; Medtronic is a Dividend Aristocrat with more than 40 years of consecutive dividend raises, supported by earnings growth and a healthy balance sheet. Share buybacks are reducing the share count incrementally each quarter and are expected to continue at a similar pace for the foreseeable future. 

Medtronic Fires on All Cylinders in Q2 F2026

Medtronic delivered a strong FQ2, with growth across all segments and $8.96 billion in net revenue. That represents a 6.6% year-over-year increase — an acceleration from the prior year that narrowly outpaced consensus.

Growth was driven by organic expansion (+5.5%) and a 10.8% increase in the Cardiovascular portfolio, led by a 71% jump in sales of cardiac ablation solutions. Diabetes sales rose 10.3% year over year, with smaller gains in the Neurosciences and Medical-Surgical segments. 

Margins also improved. Operational execution and the absence of tariff-related surprises helped expand margins and accelerate bottom-line gains. Adjusted earnings rose 8% versus a 6.6% revenue gain, outperforming MarketBeat’s consensus by a wider margin, and the company expects the strength to continue. 

Q2 momentum prompted management to raise its full-year guidance and boost market sentiment. The company increased its organic growth forecast by 50 basis points to 5.5%, nudging the midpoint of the EPS range above consensus. Management may raise targets again following FQ3.

Institutional and Analyst Trends Indicate Accumulation Underway

Institutional and analyst trends suggest accumulation is underway. Institutions — which own more than 80% of the stock — have been buying steadily over the trailing 12 months and increased activity in late Q3 and early Q4. 

That institutional base provides strong support and a market tailwind, a trend also reflected in analyst data. Analyst trends show expanded coverage, firmer sentiment, and upward price-target revisions; the consensus target of $103 implies modest upside, while recent updates point to larger gains.

The question now is whether these investors and analysts will continue to buy and lift targets — Q2 developments suggest they will. 

Post-release price action was solid: the stock jumped about 5% soon after the open, confirming support at a key pivot — the prior resistance and top of a trading range — and set a new high. That completed a technical reversal and opens the door to a sustainable rally.

Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AM newsletter that covers stories that will impact the stock market each day.

This email content is a sponsored message for Golden Portfolio, a third-party advertiser of The Early Bird and MarketBeat. 

If you need assistance with your subscription, please feel free to contact MarketBeat’s U.S. based support team at contact@marketbeat.com.

If you no longer wish to receive email from The Early Bird, you can unsubscribe.

© 2006-2025 MarketBeat Media, LLC. 
345 N Reid Place #620, Sioux Falls, S.D. 57103-7078. U.S.A..

From Our Partners: Punch these codes into your ordinary brokerage account (From Brownstone Research)